Novartis AG $NVS Stock Holdings Lifted by Cwm LLC

Key Points

• Cwm LLC increased its holdings in Novartis AG by 19.8%, owning 82,659 shares valued at approximately $10 million as of its latest SEC filing.
• Several institutional investors, including Brighton Jones LLC and GAMMA Investing LLC, have made significant adjustments to their positions in Novartis, reflecting growing interest in the stock.
• Analysts have mixed ratings on Novartis, with a consensus of Hold, and a target price averaging $120.33, highlighting a range of opinions from Strong Buy to Sell.

Cwm LLC lifted its position in Novartis AG (NYSE:NVS - Free Report) by 19.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 82,659 shares of the company's stock after acquiring an additional 13,687 shares during the period. Cwm LLC's holdings in Novartis were worth $10,003,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in NVS. Brighton Jones LLC grew its position in Novartis by 76.5% during the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock valued at $599,000 after purchasing an additional 2,666 shares in the last quarter. GAMMA Investing LLC grew its position in Novartis by 29.9% during the first quarter. GAMMA Investing LLC now owns 6,524 shares of the company's stock valued at $727,000 after purchasing an additional 1,500 shares in the last quarter. Trust Point Inc. purchased a new position in Novartis during the first quarter valued at approximately $613,000. Sowell Financial Services LLC purchased a new position in Novartis during the first quarter valued at approximately $722,000. Finally, Sagespring Wealth Partners LLC grew its position in Novartis by 67.7% during the first quarter. Sagespring Wealth Partners LLC now owns 5,759 shares of the company's stock valued at $642,000 after purchasing an additional 2,325 shares in the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. The Goldman Sachs Group reaffirmed a "sell" rating and set a $118.00 price objective (down from $119.00) on shares of Novartis in a research report on Friday, September 12th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Novartis in a research report on Wednesday, October 8th. Morgan Stanley upgraded shares of Novartis from an "underweight" rating to an "equal weight" rating and set a $123.00 target price for the company in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Novartis in a research note on Thursday, August 21st. Finally, Wall Street Zen upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $120.33.

Novartis Price Performance

Shares of Novartis stock opened at $130.31 on Wednesday. The firm has a fifty day simple moving average of $125.62 and a 200-day simple moving average of $118.16. The company has a current ratio of 0.82, a quick ratio of 0.62 and a debt-to-equity ratio of 0.53. Novartis AG has a 1-year low of $96.06 and a 1-year high of $133.55. The stock has a market capitalization of $275.27 billion, a price-to-earnings ratio of 18.97, a PEG ratio of 1.79 and a beta of 0.64.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The company reported $2.42 earnings per share for the quarter, topping analysts' consensus estimates of $2.38 by $0.04. Novartis had a net margin of 25.64% and a return on equity of 41.08%. The business had revenue of $14.05 billion during the quarter, compared to analysts' expectations of $13.94 billion. During the same period in the previous year, the company earned $1.97 earnings per share. Novartis's revenue for the quarter was up 12.3% on a year-over-year basis. On average, sell-side analysts expect that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.